Abstract：FLT3 mutation-internal tandem duplication (FLT3-ITD)mutation is a common type of mutation in acute myeloid leukemia (AML),which is closely related to the occurrence,development and poor prognosis of AML.DNA methylation transferase 3A (DNM-T3A)mutation has a high frequency in AML.About 60%DNMT3A mutations happened at codon R882.DNMT3A R882 mutation plays an important role in the development of AML,and suggests poor prognosis.In recent years,studies have found that FLT3-ITD and DNMT3A R882 mutations are both factors for poor prognosis of AML.Combined with the results of current research,this paper summarizes the pathogenesis,synergy,clinical characteri-stics,treatment and prognosis of combined mutation of FLT3-ITD and DNMT3A R882 in AML.
杨槟荧. FLT3-ITD和DNMT3A R882基因联合突变在急性髓系白血病中的研究进展[J]. 中国当代医药, 2018, 25(15): 26-29.
YANG Bin-ying. Research progress of combined mutation of FLT3-ITD and DNMT3A R882 gene in acute myeloid leukemia. 中国当代医药, 2018, 25(15): 26-29.
Marcucci G，Metzeler KH，Schwind S，et al.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia[J].J Clin Oncol，2012，30（7）：742-750.
[2]
Pemmaraju N，Kantarjian H，Andreeff M，et al.Investigational FMS-like tyrosine kinase3 inhibitors in treatment of acute myeloid leukemia[J].Expert Opin Investig Drugs，2014，23（7）：943-954.
[3]
Govedarovic N，Marjanovic G.Frequency and prognostic impact of FLT3-ITD mutation in patients with acute myeloid leukemia[J].J BUON，2011，16（1）：108-111.
[4]
Yang L，Rau R，Goodell MA，et al.DNMT3A in haematological malignancies[J].Nature Reviews Cancer，2015，15（3）：152-165.
[5]
Holz-Schietinger C，Matje DM，Reich NO，et al.Mutations in DNAmethyltransferase（DNMT3A）observed in acute myeloid leukemia patients disrupt processive methylation[J].J Biol Chem，2012，287（37）：30941-30951.
[6]
Russler-GermainDA，SpencerDH，YoungMA，etal.TheR882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers[J].Cancer Cell，2014，25（4）：442-454.
[7]
Brunetti L，Gundry MC，Goodell MA，et al.DNMT3A in Leukemia[J].Cold Spring Harb Perspect Med，2017，7（2）：303-320.
[8]
Kim SJ，Zhao H，Hardikar S，et al.ADNMT3A mutation com-mon in AML exhibits dominant-negative effects in murine ES cells[J].Blood，2013，122（25）：4086-4089.
[9]
Mayle A，Yang L，Rodriguez B，et al.Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation[J].Blood，2015，125（4）：629-638.
Yang L，Rodriguez B，Luo M，et al.Dnmt3a-deletion accelerates FLT3-ITD malignancies in mice by hypomethylation of enhancer sites and activating stem cell programs;implications for therapy[J].Blood，2013，122（2）：21-59.
[12]
Guryanova OA，Lieu YK，Garrett-Bakelman FE，et al.Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells[J].Leukemia，2016，30（5）： 1133-1142.
[13]
Meyer SE，Qin T，Muench DE，et al.DNMT3A haploinsufficiency transforms FLT3-ITD myeloproliferative disease into a rapid，spontaneous，and fully penetrant acute myeloid leukemia[J].Cancer Discov，2016，6（5）：501-515.
[14]
Yang L，Rodriguez B，Mayle A，et al.DNMT3A loss drives enhancer hypomethylation in FLT3-ITD associated leukemias[J].Cancer Cell，2016，29（6）：922-934.
[15]
Poitras JL，Heiser D，Li L，et al.Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model[J].Oncotarget，2016，7（43）：69124-69135.
[16]
Tang S，Shen H，Wu D，et al.FLT3-ITD with DNMT3A R882 doublemutationisapoorprognosticfactorinChinesepatients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation[J].Int J Hematol，2017，106（4）：552-561.
[17]
Ahn JS，Kim HJ，Kim YK，et al.DNMT3A R882 mutation with FLT3-ITD positivity is an extremely poor prognostic factor in patients with normal-karyotype acute myeloid leukemia after allogeneic hematopoietic cell transplantation[J].Biol Blood Marrow Transplant，2016，22（1）：61-70.
[18]
Gaidzik VI，Schlenk RF，Paschka P，et al.Clinical impact of DNMT3A mutations in younger adult patients with acute myeloidleukemia：resultsoftheAMLStudyGroup（AMLSG）[J].Blood，2013，121（23）：4769-4777.
[19]
Gale RE，Lamb K，Allen C，et al.Simpson′s paradox and the impactofdifferentDNMT3Amutationsonoutcomeinyounger adults with acute myeloid leukemia[J].J Clin Oncol，2015，33（18）：2072-2083.
[20]
Renneville A，Boissel N，Nibourel O，et al.Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia：a study by the Acute Leukemia French Association[J].Leukemia，2012，26（6）：1247-1254.
[21]
Hou HA，Kuo YY，Liu CY，et al.DNMT3A mutations in acute myeloid leukemia：stability during disease evolution and clinical implications[J].Blood，2012，119（2）：559-568.
O′Donnell MR，Tallman MS，Abboud CN，et al.Acute Myeloid Leukemia，Version 3.2017，NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw，2017，15（7）：926-957.
[25]
Tian H，Xu Y，Liu L，et al.Comparison of outcomes in mixed phenotypeacuteleukemiapatientstreatedwithchemotherapy and stem cell transplantation versus chemotherapy alone[J].Leuk Res，2016，45：40-46.
京公网安备 11010502046607号